ANIKA THERAPEUTICS INC (ANIK)

US0352551081 - Common Stock

25.57  -0.01 (-0.04%)

After market: 25.57 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028
Revenue
YoY % growth
147.8M
13.26%		156.2M
5.68%		166.662M
6.70%		173.82M
4.29%
EBITDA
YoY % growth
16.92M
-38.83%		-4.92M
-129.08%		-11.232M
-128.29%		26.739M
338.06%
EBIT
YoY % growth
2.6M
-81.69%		-19.4M
-846.15%		-25.449M
-31.18%		-2.331M
90.84%		N/AN/A
Operating Margin
1.76%-12.42%-15.27%-1.34%N/AN/A
EPS
YoY % growth
0.29
145.31%		-0.89
-406.90%		-5.41
-507.87%		0.01
100.09%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.11
76.13%
Revenue
Q2Q % growth		39.999M
5.48%
EBITDA
Q2Q % growth		4.531M
EBIT
Q2Q % growth		-2.609M
69.20%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -4.30
-1,164.71%		-0.27-4.03-1,500.91%
Q3 2023
Q2Q % growth		 -0.45
-200.00%		-0.38-0.07-18.17%
Q2 2023
Q2Q % growth		 -0.19
5.00%		-0.280.0931.01%
Q1 2023
Q2Q % growth		 -0.47
-135.00%		-0.31-0.16-53.59%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 42.971M
8.46%		42.233M738K1.75%
Q3 2023
Q2Q % growth		 41.47M
3.01%		39.031M2.439M6.25%
Q2 2023
Q2Q % growth		 44.3M
11.70%		41.368M2.932M7.09%
Q1 2023
Q2Q % growth		 37.92M
3.35%		38.026M-106K-0.28%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 49.23% 101.6% 101.08%
Revenue0% -5.62% -5.02% -5.02%